Mechanisms of resistance among respiratory tract pathogens

Clinics in Laboratory Medicine

Volumn 24, Issue 2, 2004, Pages 419-453

  Jacobs, Michael R ^a   Anon, Jack ^b   Appelbaum, Peter C ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL DNA; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CEFACLOR; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CHLORAMPHENICOL; CLARITHROMYCIN; CLAVULANIC ACID; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; PROTEIN SYNTHESIS INHIBITOR; PUROMYCIN; QUINOLONE DERIVATIVE; STREPTOGRAMIN; TETRACYCLINE; UNINDEXED DRUG;

AMINO ACID METABOLISM; ANTIBIOTIC RESISTANCE; BACTERIAL CELL WALL; BACTERIAL FLORA; BACTERIAL GROWTH; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL TRANSLOCATION; CHRONIC BRONCHITIS; COMMUNITY ACQUIRED PNEUMONIA; DISEASE COURSE; DISEASE EXACERBATION; DNA REPLICATION; EFFUSION; ENZYME ACTIVITY; GENE MUTATION; HAEMOPHILUS INFLUENZAE; HEALTH CARE MANAGEMENT; HUMAN; MEDICAL EDUCATION; MEDICAL INFORMATION; MICROBIAL ACTIVITY; MORAXELLA CATARRHALIS; NONHUMAN; OTITIS MEDIA; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PUBLIC HEALTH SERVICE; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTION; REVIEW; RHINITIS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HAEMOPHILUS INFLUENZAE; HUMANS; MORAXELLA (BRANHAMELLA) CATARRHALIS; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 2942590738     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2004.03.011     Document Type: Review

References (124)

1. Dagan R., Abramson O., Leibovitz E., et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr Infect Dis J. 15:(11):1996;980-985
2. Dagan R., Leibovitz E., Greenberg D., Yagupsky P., Fliss D.M., Leiberman A. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatr Infect Dis J. 17:(9):1998;776-782
3. Dagan R., Johnson C.E., McLinn S., et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J. 19:(2):2000;95-104
4. Brook I., Gober A.E. Microbiologic characteristics of persistent otitis media. Arch Otolaryngol Head Neck Surg. 124:(12):1998;1350-1352
5. Pallares R., Linares J., Vadillo M., et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 333:(8):1995;474-480
6. Friedland I.R. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J. 14:(10):1995;885-890
7. Buckingham S.C., Brown S.P., Joaquin V.H. Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. J Pediatr. 132:(1):1998;174-176
8. Dowell S.F., Butler J.C., Giebink G.S., et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance-a report from the drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J. 18:(1):1999;1-9
9. Turett G.S., Blum S., Fazal B.A., Justman J.E., Telzak E.E. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis. 29:(2):1999;321-327
10. Feikin D.R., Schuchat A., Kolczak M., et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 90:(2):2000;223-229
11. Scott J.A., Hall A.J., Muyodi C., et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet. 355:(9211):2000;1225-1230
12. Metlay J.P., Hofmann J., Cetron M.S., et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 30:(3):2000;520-528
13. Garcia-Bustos J., Tomasz A. A biological price of antibiotic resistance: major changes in the peptidoglycan structure of penicillin-resistant pneumococci. Proc Natl Acad Sci USA. 87:(14):1990;5415-5419
14. Magnusdottir A.B., Hermansson A., Melhus A. Experimental study of the virulence of Streptococcus pneumoniae with reduced susceptibility to penicillin. Int J Pediatr Otorhinolaryngol. 55:(1):2000;1-9
15. Rocha P., Baleeiro C., Tunkel A.R. Impact of antimicrobial resistance on the treatment of invasive pneumococcal infections. Curr Infect Dis Rep. 2:(5):2000;399-408
16. Winston L.G., Perlman J.L., Rose D.A., Gerberding J.L. Penicillin-nonsusceptible Streptococcus pneumoniae at San Francisco General Hospital. Clin Infect Dis. 29:(3):1999;580-585
17. Low D.E., Kellner J.D., Wright G.D. Superbugs: how they evolve and minimize the cost of resistance. Curr Infect Dis Rep. 1:(5):1999;464-469
18. Andersson D.I., Levin B.R. The biological cost of antibiotic resistance. Curr Opin Microbiol. 2:(5):1999;489-493
19. Levy S.B. The challenge of antibiotic resistance. Sci Am. 278:(3):1998;46-53
20. Salyers A.A., Amabile-Cuevas C.F. Why are antibiotic resistance genes so resistant to elimination? Antimicrob Agents Chemother. 41:(11):1997;2321-2325
21. Lenski R.E. Bacterial evolution and the cost of antibiotic resistance. Int Microbiol. 1:(4):1998;265-270
22. McCaig L.F., Hughes J.M. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA. 273:(3):1995;214-219
23. Schappert S.M. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 1997. Vital Health Stat 13. 143:1999;i-iv. 1-39
24. Dowell S.F., Schwartz B. Resistant pneumococci: protecting patients through judicious use of antibiotics. Am Fam Physician. 55:(5):1997;1647-1654. 1657-8
25. Dowell S.F., Marcy S.M., Phillips W.R., Gerber M.A., Schwartz B. Principles of judicious use of antimicrobial agents for pediatric upper respiratory tract infections. Pediatrics. 101:1998;163-165
26. McCaig LF, Besser RE, Hughes JM. Decline in pediatric antimicrobial drug prescribing among office-based physicians in the United states, 1989-1998. Presented at 38th Infectious Disease Society of America Annual Meeting. New Orleans, Louisiana, September 2000.
27. Heffelfinger J.D., Dowell S.F., Jorgensen J.H., et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 160:(10):2000;1399-1408
28. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Sinus and Allergy Health Partnership. Otolaryngol Head Neck Surg. 123:(1 Pt 2):2000;5-31
29. Bartlett J.G., Dowell S.F., Mandell L.A., File T.M. Jr., Musher D.M., Fine M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 31:(2):2000;347-382
30. Mandell L.A., Bartlett J.G., Dowell S.F., File T.M. Jr., Musher D.M., Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis. 37:(11):2003;1405-1433
31. Anon J.B., Jacobs M.R., Poole M.D., et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 130:(1 Suppl):2004;1-45
32. Barnett E.D., Klein J.O. The problem of resistant bacteria for the management of acute otitis media. Pediatr Clin North Am. 42:(3):1995;509-517
33. Jacobs M.R. Increasing antibiotic resistance among otitis media pathogens and their susceptibility to oral agents based on pharmacodynamic parameters. Pediatr Infect Dis J. 19:(5 Suppl):2000;S47-S55. [discussion: S55-6]
34. Appelbaum P.C. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 15:(1):1992;77-83
35. Jacobs M.R., Appelbaum P.C. Antibiotic-resistant pneumococci. Rev Med Microbiol. 6:1995;77-93
36. Doern G.V. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med. 99:(6B):1995;3S-7S
37. Jacobs M.R., Bajaksouzian S., Zilles A., Lin G., Pankuch G.A., Appelbaum P.C. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US Surveillance study. Antimicrob Agents Chemother. 43:(8):1999;1901-1908
38. Jacobs M.R. Worldwide trends in antimicrobial resistance among common respiratory tract pathogens in children. Pediatr Infect Dis J. 22:(8 Suppl):2003;S109-S119
39. Appelbaum P.C., Bhamjee A., Scragg J.N., Hallett A.F., Bowen A.J., Cooper R.C. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet. 2:(8046):1977;995-997
40. Jacobs M.R., Koornhof H.J., Robins-Browne R.M., et al. Emergence of multiply resistant pneumococci. N Engl J Med. 299:(14):1978;735-740
41. Caputo G.M., Appelbaum P.C., Liu H.H. Infections due to penicillin-resistant pneumococci. Clinical, epidemiologic, and microbiologic features. Arch Intern Med. 153:(11):1993;1301-1310
42. Butler J.C., Hofmann J., Cetron M.S., Elliott J.A., Facklam R.R., Breiman R.F. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis. 174:(5):1996;986-993
43. Ronchetti MP, Zilles A, Appelbaum PC, Jacobs MR. Susceptibility of current and archived otitis media isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to contemporary oral agents. Presented at: 38th Interscience Conference on ANtimicrobial Agents and Chemotherapy. San Diego, September 1998.
44. Fasola E.L., Bajaksouzian S., Appelbaum P.C., Jacobs M.R. Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods. Antimicrob Agents Chemother. 41:(1):1997;129-134
45. Sutcliffe J., Tait-Kamradt A., Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother. 40:(8):1996;1817-1824
46. Chen D.K., McGeer A., de Azavedo J.C., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med. 341:(4):1999;233-239
47. Neu H.C. The crisis in antibiotic resistance. Science. 257:(5073):1992;1064-1073
48. Cohen M.L. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science. 257:(5073):1992;1050-1055
49. Ochman H., Lawrence J.G., Groisman E.A. Lateral gene transfer and the nature of bacterial innovation. Nature. 405:(6784):2000;299-304
50. Mazel D., Davies J. Antibiotic resistance in microbes. Cell Mol Life Sci. 56:(9-10):1999;742-754
51. Ziebuhr W., Ohlsen K., Karch H., Korhonen T., Hacker J. Evolution of bacterial pathogenesis. Cell Mol Life Sci. 56:(9-10):1999;719-728
52. Bennett P.M. Integrons and gene cassettes: a genetic construction kit for bacteria. J Antimicrob Chemother. 43:(1):1999;1-4
53. Courvalin P., Carlier C. Transposable multiple antibiotic resistance in Streptococcus pneumoniae. Mol Gen Genet. 205:(2):1986;291-297
54. Vijayakumar M.N., Priebe S.D., Guild W.R. Structure of a conjugative element in Streptococcus pneumoniae. J Bacteriol. 166:(3):1986;978-984
55. Chambers H.F. Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. J Infect Dis. 179:(Suppl 2):1999;S353-S359
56. Massova I., Mobashery S. Structural and mechanistic aspects of evolution of beta-lactamases and penicillin-binding proteins. Curr Pharm Des. 5:(11):1999;929-937
57. Ghuysen J.M. Molecular structures of penicillin-binding proteins and beta-lactamases. Trends Microbiol. 2:(10):1994;372-380
58. Blumberg P.M., Strominger J.L. Interaction of penicillin with the bacterial cell: penicillin-binding proteins and penicillin-sensitive enzymes. Bacteriol Rev. 38:(3):1974;291-335
59. Hakenbeck R., Grebe T., Zahner D., Stock J.B. beta-lactam resistance in Streptococcus pneumoniae: penicillin-binding proteins and non-penicillin-binding proteins. Mol Microbiol. 33:(4):1999;673-678
60. Hakenbeck R., Kaminski K., Konig A., et al. Penicillin-binding proteins in beta-lactam-resistant streptococcus pneumoniae. Microb Drug Resist. 5:(2):1999;91-99
61. Hasegawa K., Yamamoto K., Chiba N., et al. Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States. Microb Drug Resist. 9:(1):2003;39-46
62. Laible G., Hakenbeck R. Five independent combinations of mutations can result in low-affinity penicillin-binding protein 2x of Streptococcus pneumoniae. J Bacteriol. 173:(21):1991;6986-6990
63. Nagai K., Shibasaki Y., Hasegawa K., et al. Evaluation of PCR primers to screen for Streptococcus pneumoniae isolates and beta-lactam resistance, and to detect common macrolide resistance determinants. J Antimicrob Chemother. 48:(6):2001;915-918
64. Sibold C., Henrichsen J., Konig A., Martin C., Chalkley L., Hakenbeck R. Mosaic pbpX genes of major clones of penicillin-resistant Streptococcus pneumoniae have evolved from pbpX genes of a penicillin-sensitive Streptococcus oralis. Mol Microbiol. 12:(6):1994;1013-1023
65. Filipe S.R., Tomasz A. Inhibition of the expression of penicillin resistance in Streptococcus pneumoniae by inactivation of cell wall muropeptide branching genes. Proc Natl Acad Sci USA. 97:(9):2000;4891-4896
66. Mason E.O., Lamberth L., Lichenstein R., Kaplan S.L. Distribution of Streptococcus pneumoniae resistant to penicillin in the USA and in-vitro susceptibility to selected oral antibiotics. J Antimicrob Chemother. 36:(6):1995;1043-1048
67. Thornsberry C., Ogilvie P.T., Holley H.P. Jr., Sahm D.F. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolates to 26 antimicrobial agents: a prospective US study. Antimicrob Agents Chemother. 43:(11):1999;2612-2623
68. Bryan C.S., Talwani R., Stinson M.S. Penicillin dosing for pneumococcal pneumonia. Chest. 112:(6):1997;1657-1664
69. Harrison C.J., Welch D.F. Middle ear effusion amoxicillin concentrations in acute otitis media. Pediatr Infect Dis J. 17:(7):1998;657-658
70. Seikel K., Shelton S., McCracken G.H. Jr. Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Pediatr Infect Dis J. 17:(10):1998;969-970
71. Massova I., Mobashery S. Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. Antimicrob Agents Chemother. 42:(1):1998;1-17
72. Jordens J.Z., Slack M.P. Haemophilus influenzae: then and now. Eur J Clin Microbiol Infect Dis. 14:(11):1995;935-948
73. Rubin L.G., Medeiros A.A., Yolken R.H., Moxon E.R. Ampicillin treatment failure of apparently beta-lactamase-negative Haemophilus influenzae type b meningitis due to novel beta-lactamase. Lancet. 2:(8254):1981;1008-1010
74. Wallace R.J. Jr., Steingrube V.A., Nash D.R., et al. BRO beta-lactamases of Branhamella catarrhalis and Moraxella subgenus Moraxella, including evidence for chromosomal beta-lactamase transfer by conjugation in B. catarrhalis, M. nonliquefaciens, and M. lacunata. Antimicrob Agents Chemother. 33:(11):1989;1845-1854
75. Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev. 1:(1):1988;109-123
76. Rolinson G.N. Evolution of beta-lactamase inhibitors. Rev Infect Dis. 13:(Suppl 9):1991;S727-S732
77. Ng W.L., Kazmierczak K.M., Robertson G.T., Gilmour R., Winkler M.E. Transcriptional regulation and signature patterns revealed by microarray analyses of Streptococcus pneumoniae R6 challenged with sublethal concentrations of translation inhibitors. J Bacteriol. 185:(1):2003;359-370
78. Vazquez D., Monro R.E. Effects of some inhibitors of protein synthesis on the binding of aminoacyl tRNA to ribosomal subunits. Biochim Biophys Acta. 142:(1):1967;155-173
79. Voet D., Voet J.G., Pratt C.W. Fundamentals of biochemistry. 1999;John Wiley & Sons, Inc. New York. p. 723-931
80. Cocito C., Di Giambattista M., Nyssen E., Vannuffel P. Inhibition of protein synthesis by streptogramins and related antibiotics. J Antimicrob Chemother. 39:(Suppl A):1997;7-13
81. Mazzei T., Mini E., Novelli A., Periti P. Chemistry and mode of action of macrolides. J Antimicrob Chemother. 31:(Suppl C):1993;1-9
82. Widdowson C.A., Klugman K.P. Molecular mechanisms of resistance to commonly used non-betalactam drugs in Streptococcus pneumoniae. Semin Respir Infect. 14:(3):1999;255-268
83. Tait-Kamradt A., Davies T., Cronan M., Jacobs M.R., Appelbaum P.C., Sutcliffe J. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother. 44:(8):2000;2118-2125
84. Tait-Kamradt A., Davies T., Appelbaum P.C., et al. Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother. 44:(12):2000;3395-3401
85. Shortridge V.D., Flamm R.K., Ramer N., Beyer J., Tanaka S.K. Novel mechanism of macrolide resistance in Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 26:(2):1996;73-78
86. Tait-Kamradt A., Clancy J., Cronan M., et al. mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother. 41:(10):1997;2251-2255
87. Lonks J.R., Garau J., Gomez L., et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis. 35:(5):2002;556-564
88. Nagai K, Shibasaki Y, Hasegawa K. Rapid identification and penicillin and macrolide resistance screening of Streptococcus pneumoniae isolated from US and Europe by PCR. Presented at 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Canada, September 2000.
89. Bryskier A. Ketolides-telithromycin, an example of a new class of antibacterial agents. Clin Microbiol Infect. 6:(12):2000;661-669
90. Davies T.A., Ednie L.M., Hoellman D.M., Pankuch G.A., Jacobs M.R., Appelbaum P.C. Antipneumococcal activity of ABT-773 compared to those of 10 other agents. Antimicrob Agents Chemother. 44:(7):2000;1894-1899
91. Zhong P., Cao Z., Hammond R., et al. Induction of ribosome methylation in MLS-resistant Streptococcus pneumoniae by macrolides and ketolides. Microb Drug Resist. 5:(3):1999;183-188
92. Sanchez L., Leranoz S., Puig M., Loren J.G., Nikaido H., Vinas M. Molecular basis of antimicrobial resistance in non-typable Haemophilus influenzae. Microbiologia. 13:(3):1997;309-314
93. Sanchez L., Pan W., Vinas M., Nikaido H. The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. J Bacteriol. 179:(21):1997;6855-6857
94. Chopra I., Hawkey P.M., Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother. 29:(3):1992;245-277
95. Burdett V., Inamine J., Rajagopalan S. Heterogeneity of tetracycline resistance determinants in Streptococcus. J Bacteriol. 149:(3):1982;995-1004
96. Widdowson C.A., Klugman K.P., Hanslo D. Identification of the tetracycline resistance gene, tet(O), in Streptococcus pneumoniae. Antimicrob Agents Chemother. 40:(12):1996;2891-2893
97. Wang J.C. DNA topoisomerases. Annu Rev Biochem. 54:1985;665-697
98. Kato J., Nishimura Y., Imamura R., Niki H., Hiraga S., Suzuki H. New topoisomerase essential for chromosome segregation in E. coli. Cell. 63:(2):1990;393-404
99. Kato J., Suzuki H., Ikeda H. Purification and characterization of DNA topoisomerase IV in Escherichia coli. J Biol Chem. 267:(36):1992;25676-25684
100. Pan X.S., Fisher L.M. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother. 42:(11):1998;2810-2816
101. Tankovic J., Perichon B., Duval J., Courvalin P. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother. 40:(11):1996;2505-2510
102. Khodursky A.B., Zechiedrich E.L., Cozzarelli N.R. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci USA. 92:(25):1995;11801-11805
103. Munoz R., De La Campa A.G. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother. 40:(10):1996;2252-2257
104. Davies T.A., Kelly L.M., Hoellman D.B., et al. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother. 44:(3):2000;633-639
105. Davies T.A., Kelly L.M., Pankuch G.A., Credito K.L., Jacobs M.R., Appelbaum P.C. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Antimicrob Agents Chemother. 44:(2):2000;304-310
106. Baranova N.N., Neyfakh A.A. Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae. Antimicrob Agents Chemother. 41:(6):1997;1396-1398
107. Kaatz G.W., Seo S.M., Ruble C.A. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 37:(5):1993;1086-1094
108. Gill M.J., Brenwald N.P., Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 43:(1):1999;187-189
109. Hartman P.G. Molecular aspects and mechanism of action of dihydrofolate reductase inhibitors. J Chemother. 5:(6):1993;369-376
110. Burchall J.J., Hitchings G.H. Inhibitor binding analysis of dihydrofolate reductases from various species. Mol Pharmacol. 1:(2):1965;126-136
111. Then R., Angehrn P. Nature of the bacterial action of sulfonamides and trimethoprim, alone and in combination. J Infect Dis. 128:(Suppl):1973;498-501
112. Adrian P.V., Klugman K.P. Mutations in the dihydrofolate reductase gene of trimethoprim-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 41:(11):1997;2406-2413
113. Maskell J.P., Sefton A.M., Hall L.M. Multiple mutations modulate the function of dihydrofolate reductase in trimethoprim-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 45:(4):2001;1104-1108
114. Pikis A., Donkersloot J.A., Rodriguez W.J., Keith J.M. A conservative amino acid mutation in the chromosome-encoded dihydrofolate reductase confers trimethoprim resistance in Streptococcus pneumoniae. J Infect Dis. 178:(3):1998;700-706
115. Maskell J.P., Sefton A.M., Hall L.M. Mechanism of sulfonamide resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 41:(10):1997;2121-2126
116. de Groot R., Chaffin D.O., Kuehn M., Smith A.L. Trimethoprim resistance in Haemophilus influenzae is due to altered dihydrofolate reductase(s). Biochem J. 274:(Pt 3):1991;657-662
117. Burman L.G. The antimicrobial activities of trimethoprim and sulfonamides. Scand J Infect Dis. 18:(1):1986;3-13
118. Bluestone C.D., Stephenson J.S., Martin L.M. Ten-year review of otitis media pathogens. Pediatr Infect Dis J. 11:(8 Suppl):1992;S7-S11
119. Jacobs M.R. Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media. Pediatr Infect Dis J. 15:(10):1996;940-943
120. Sethi S. Etiology and management of infections in chronic obstructive pulmonary disease. Clin Pulm Med. 6:1999;327-332
121. Gwaltney J.M. Jr., Scheld W.M., Sande M.A., Sydnor A. The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol. 90:(3 Pt 2):1992;457-461. [discussion 462]
122. Berg O., Carenfelt C., Kronvall G. Bacteriology of maxillary sinusitis in relation to character of inflammation and prior treatment. Scand J Infect Dis. 20:(5):1988;511-516
123. Bartlett J.G., Mundy L.M. Community-acquired pneumonia. N Engl J Med. 333:(24):1995;1618-1624
124. Wald E.R., Reilly J.S., Casselbrant M., et al. Treatment of acute maxillary sinusitis in childhood: a comparative study of amoxicillin and cefaclor. J Pediatr. 104:(2):1984;297-302